{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:07:27Z","timestamp":1788527247234,"version":"build-2803163510"},"reference-count":75,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme Corp"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2019,10,3]]},"DOI":"10.1080\/13696998.2019.1609485","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T13:15:14Z","timestamp":1556025314000},"page":"981-993","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States"],"prefix":"10.1080","volume":"22","author":[{"given":"Arielle G.","family":"Bensimon","sequence":"first","affiliation":[{"name":"Analysis Group Inc., Boston, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Boston, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Boston, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Boston, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc., Kenilworth, NJ, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Xiaoqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc., Kenilworth, NJ, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshu","family":"Wang","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc., Kenilworth, NJ, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Aguiar-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Merck Sharp and Dohme BV, Harleem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"CIT0001","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer stat facts: melanoma of the skin; [cited 2018 Oct 30]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html"},{"key":"CIT0002","first-page":"1005","volume":"28","author":"Rastrelli M","year":"2014","journal-title":"In Vivo"},{"key":"CIT0003","unstructured":"American Cancer Society. Survival Rates for Melanoma; 2016 [cited 2018 October 31]. Available from: https:\/\/www.cancer.org\/cancer\/melanoma-skin-cancer\/detection-diagnosis-staging\/survival-rates-for-melanoma-skin-cancer-by-stage.html"},{"key":"CIT0004","unstructured":"Stone M. Surgical management of metastatic melanoma: UpToDate; 2016 [cited 2018 October 30]. Available from: https:\/\/www.uptodate.com\/contents\/surgical-management-of-metastatic-melanoma"},{"key":"CIT0005","unstructured":"Mayo Clinic. Melanoma diagnosis and treatment 2016 [cited 2018 October 31]. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/melanoma\/diagnosis-treatment\/drc-20374888"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200241"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.05.005"},{"key":"CIT0008","unstructured":"National Comprehensive Cancer Network. Melanoma. NCCN clinical practice guidelines in oncology. Version 1.2019. [cited 2019 Feb 15]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199703000-00015"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0123"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2444"},{"key":"CIT0012","first-page":"S11","volume":"6","author":"Atkins MB","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30700-9"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"CIT0021","unstructured":"Food and Drug Administration. Highlights of Prescribing Information; 2011 [cited 2018 October 30]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125377s087lbl.pdf"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S92546"},{"key":"CIT0023","unstructured":"European Medicines Agency. Yervoy: EPAR \u2013 Product Information. 2011 [cited 2018 July 26]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yervoy."},{"key":"CIT0024","unstructured":"Merck & Co. Keytruda (pembrolizumab): prescribing information; 2018. [cited 2018 July 26]. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"key":"CIT0025","unstructured":"Committee for Medicinal Products for Human Use. Summary of opinion (post authorisation): Keytruda; 2018 [cited 2018 July 26]. Available from: https:\/\/www.ema.europa.eu\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-42ii-43_en.pdf"},{"key":"CIT0026","unstructured":"European Society for Medical Oncology. EMA recommends pembrolizumab for the adjuvant treatment of melanoma; 2018 [cited 2018 October 25]. Available from: https:\/\/www.esmo.org\/Oncology-News\/EMA-Recommends-Pembrolizumab-for-the-Adjuvant-Treatment-of-Melanoma"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.2.184"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.05.009"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.1150"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2351"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.7284"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.74005.x"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00304-X"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00413-3"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"CIT0036","unstructured":"Bureau of Labor Statistics. Consumer price index: Medical care commodities in U.S. city average, all urban consumers, not seasonally adjusted. 2019. [cited 2019 Jan 5]. Available from: https:\/\/beta.bls.gov\/dataViewer\/view\/timeseries\/CUUR0000SAM1"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16651869"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16670617"},{"key":"CIT0039","first-page":"1","volume":"66","author":"Arias E","year":"2017","journal-title":"Natl Vital Stat Rep"},{"key":"CIT0040","unstructured":"Flatiron Health. Flatiron database. 2018. [cited 2018 Dec 15]. Available from: http:\/\/www.flatiron.com\/real-world-evidence"},{"key":"CIT0041","unstructured":"National Institute for Health and Care Excellence. DSU Technical Support Document 19: Partitioned survival analysis for decision modelling in health care: a critical review. 2017. [cited 2018 March 19]. Available from: http:\/\/nicedsu.org.uk\/technical-support-documents\/partitioned-survival-analysis-tsd\/"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712"},{"key":"CIT0043","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [cited 2019 Jan 5]. Available from: http:\/\/www.R-project.org\/"},{"key":"CIT0044","unstructured":"National Institute for Health and Care Excellence. DSU Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials \u2013 extrapolation with patient-level data; 2013. [cited 2018 March 9]. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf"},{"key":"CIT0045","volume-title":"Decision modelling for health economic evaluation","author":"Briggs A","year":"2011"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70012-9"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200503000-00003"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605187"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3673-y"},{"key":"CIT0055","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule Search;2018. [cited 2019 Jan 5]. Available from: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx"},{"key":"CIT0056","unstructured":"Bristol-Myers Squibb Company. Opdivo (nivolumab): prescribing information; 2018. [cited 2018 Dec 17]. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf"},{"key":"CIT0057","unstructured":"Bristol-Myers Squibb Company. Yervoy (ipilimumab): prescribing information; 2018. [cited 2018 Dec 17]. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_yervoy.pdf"},{"key":"CIT0058","unstructured":"Genentech. Cotellic (cobimetinib): prescribing information; 2015. [cited 2018 Dec 17]. Available from: https:\/\/www.gene.com\/download\/pdf\/cotellic_prescribing.pdf"},{"key":"CIT0059","unstructured":"Genentech. Zelboraf (vemurafenib): prescribing information; 2017. [cited 2018 Dec 17]. Available from: https:\/\/www.gene.com\/download\/pdf\/zelboraf_prescribing.pdf"},{"key":"CIT0060","unstructured":"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib): prescribing information; 2018. [cited 2018 Dec 17]. Available from: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/tafinlar.pdf"},{"key":"CIT0061","unstructured":"Novartis Pharmaceuticals Corporation. Mekinist (trametinib): prescribing information; 2018. [cited 2018 Dec 17]. Available from: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/mekinist.pdf"},{"key":"CIT0062","unstructured":"National Institute for Health and Care Excellence. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma [TA319]; 2014. [cited 2018 March 9]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta319"},{"key":"CIT0063","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab [TA357]; 2015. [cited 2018 March 9]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta357"},{"key":"CIT0064","unstructured":"Centers for Medicare & Medicaid Services. Acute inpatient prospective payment system. 2018. [Cited 2019 Jan 9]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/AcuteInpatientPPS\/FY2018-IPPS-Final-Rule-Home-Page.html"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S105618"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.739226"},{"key":"CIT0068","first-page":"397","volume":"7","author":"Zhang Y","year":"2015","journal-title":"CEOR"},{"key":"CIT0069","unstructured":"Merck S, Dohme C. Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: a randomized, double-blind Phase 3 trial of the EORTC Melanoma Group: Clinical study report. 2018. Data cutoff date: 2 Oct 2017. Data on file."},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.389"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.4236\/jct.2015.610091"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000469"},{"key":"CIT0073","unstructured":"Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017\u20132019."},{"key":"CIT0074","unstructured":"Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017-2019. 2018. [cited 2019 Feb 1]. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2017\/06\/ICER-value-assessment-framework-Updated-050818.pdf"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx133"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tandfonline.com\/doi\/pdf\/10.1080\/13696998.2019.1609485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2019.1609485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T06:17:46Z","timestamp":1599373066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2019.1609485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["10.1080\/13696998.2019.1609485"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2019.1609485","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}